Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,236,983
  • Shares Outstanding, K 37,782
  • Annual Sales, $ 17,450 K
  • Annual Income, $ -135,890 K
  • 60-Month Beta 1.10
  • Price/Sales 70.60
  • Price/Cash Flow N/A
  • Price/Book 4.47
Trade TARS with:

Options Overview Details

View History
  • Implied Volatility 82.87% ( +8.23%)
  • Historical Volatility 55.56%
  • IV Percentile 48%
  • IV Rank 43.31%
  • IV High 144.49% on 09/14/23
  • IV Low 35.79% on 10/31/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 40
  • Volume Avg (30-Day) 63
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 1,259
  • Open Int (30-Day) 1,180

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.02
  • Number of Estimates 6
  • High Estimate -0.83
  • Low Estimate -1.24
  • Prior Year -1.17
  • Growth Rate Est. (year over year) +12.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.40 +4.46%
on 06/07/24
39.64 -17.26%
on 05/15/24
-5.57 (-14.52%)
since 05/13/24
3-Month
28.42 +15.41%
on 03/14/24
42.50 -22.82%
on 05/09/24
+1.45 (+4.63%)
since 03/13/24
52-Week
12.57 +160.94%
on 10/17/23
42.50 -22.82%
on 05/09/24
+13.85 (+73.09%)
since 06/13/23

Most Recent Stories

More News
Why Shares of Tarsus Pharmaceuticals Are Up Thursday

The company's lead therapy is getting close to the finish line of FDA approval.

TARS : 33.41 (+2.05%)
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -9.86% and 71.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

APLS : 43.18 (+1.60%)
TARS : 33.41 (+2.05%)
Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could...

TARS : 33.41 (+2.05%)
ILMN : 108.62 (+0.10%)
Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know

Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRVB : 24.98 (+3.10%)
TARS : 33.41 (+2.05%)
Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?

Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...

TARS : 33.41 (+2.05%)
RPTX : 3.96 (-0.75%)
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

TARS : 33.41 (+2.05%)
DNA : 0.5053 (-0.45%)
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -140% and 95.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

XOMA : 25.01 (+4.21%)
TARS : 33.41 (+2.05%)
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

STOK : 17.35 (+0.93%)
TARS : 33.41 (+2.05%)
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

TARS : 33.41 (+2.05%)
Tarsus to Present at the Jefferies 2022 Healthcare Conference

IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

TARS : 33.41 (+2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 34.93
2nd Resistance Point 34.45
1st Resistance Point 33.60
Last Price 33.41
1st Support Level 32.27
2nd Support Level 31.79
3rd Support Level 30.94

See More

52-Week High 42.50
Last Price 33.41
Fibonacci 61.8% 31.07
Fibonacci 50% 27.53
Fibonacci 38.2% 24.00
52-Week Low 12.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar